Hybrid Cognitive Behavioral Therapy With Interoceptive Exposure for Irritable Bowel Syndrome: A Feasibility Study.
cognitive behavioral therapy with interoceptive exposure
complementary video materials
feasibility study
hybrid CBT
irritable bowel syndrome
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
02
2021
accepted:
23
07
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, which severely impairs the quality of life of patients. Treatment of refractory IBS patients is needed, but it is not yet widely available. Therefore, we previously developed a Japanese version of cognitive behavioral therapy with interoceptive exposure (CBT-IE) involving 10 face-to-face sessions to treat refractory IBS patients. To disseminate this treatment of IBS in places where therapists are limited, we further developed a hybrid CBT-IE program with complementary video materials that include psychoeducation and homework instructions so that patients can prepare for face-to-face sessions in advance at home and the session time can be shortened, thereby reducing the burden on both patient and therapist. In this study, we conducted a trial to evaluate the feasibility, efficacy, and safety of the hybrid CBT-IE program for Japanese IBS patients. The study was a single-arm, open-label pilot clinical trial. A total of 16 IBS patients were included in the study and 14 patients completed the intervention, which consisted of 10 weekly individual hybrid CBT-IE sessions. We performed an intention to treat analysis. The primary outcome measure for the efficacy of the intervention was a decrease in the severity of IBS symptoms. The feasibility and safety of the intervention were examined by the dropout rate and recording of adverse events, respectively. The dropout rate of the hybrid CBT-IE was comparable to that of our previous CBT-IE with only face-to-face sessions and no adverse events were recorded. The severity of IBS symptoms within-group was significantly decreased from the baseline to mid-treatment [Hedges' g = -0.98 (-1.54, -0.41)], post-treatment [Hedges' g = -1.48 (-2.09, -0.88)], 3-month follow-up [Hedges' g = -1.78 (-2.41, -1.14)], and 6-month follow-up [Hedges' g = -1.76 (-2.39, -1.13)]. Our results suggest that the hybrid CBT-IE is effective and could be conducted safely. To confirm the effectiveness of the hybrid CBT-IE, it is necessary to conduct a multicenter, parallel-design randomized control trial.
Identifiants
pubmed: 34566709
doi: 10.3389/fpsyt.2021.673939
pmc: PMC8458884
doi:
Types de publication
Journal Article
Langues
eng
Pagination
673939Informations de copyright
Copyright © 2021 Funaba, Kawanishi, Fujii, Higami, Tomita, Maruo, Sugawara, Oe, Kura, Horikoshi, Ohara, Kikuchi, Ariga, Fukudo, Sekiguchi and Ando.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pain. 2001 Jul;93(1):7-14
pubmed: 11406333
J Psychosom Res. 2013 Aug;75(2):113-20
pubmed: 23915766
Clin Transl Sci. 2011 Oct;4(5):332-7
pubmed: 22029804
Clin Gastroenterol Hepatol. 2021 Mar;19(3):538-546.e8
pubmed: 32184185
J Clin Psychiatry. 2001;62 Suppl 8:28-36; discussion 37
pubmed: 12108819
Biopsychosoc Med. 2019 Jun 6;13:14
pubmed: 31178921
Nat Rev Dis Primers. 2016 Mar 24;2:16014
pubmed: 27159638
Percept Mot Skills. 1989 Oct;69(2):611-7
pubmed: 2813009
Ann Intern Med. 2011 Jul 5;155(1):39-51
pubmed: 21727292
Aliment Pharmacol Ther. 2002 Jun;16(6):1171-85
pubmed: 12030961
Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
pubmed: 9146781
J Clin Epidemiol. 1998 Nov;51(11):1037-44
pubmed: 9817121
Aliment Pharmacol Ther. 2004 Jul 1;20(1):89-97
pubmed: 15225175
BMC Gastroenterol. 2020 Feb 4;20(1):29
pubmed: 32019509
Gut. 1997 Oct;41(4):505-12
pubmed: 9391250
Gastroenterology. 2021 Jan;160(1):99-114.e3
pubmed: 32294476
Behav Res Ther. 2014 Apr;55:27-39
pubmed: 24584055
J Psychosom Res. 2003 Dec;55(6):501-5
pubmed: 14642979
Psychiatry Res. 2002 Jul 31;110(3):291-9
pubmed: 12127479
J Gastroenterol. 2015 Jan;50(1):11-30
pubmed: 25500976
J Gastroenterol. 2006 May;41(5):491-4
pubmed: 16799892
Soc Cogn Affect Neurosci. 2013 Mar;8(3):259-66
pubmed: 22977199
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1500-1508.e3
pubmed: 30613000
Gastroenterology. 2016 Feb;150(2):358-66.e8
pubmed: 26551550
Behav Res Ther. 2011 Jan;49(1):58-61
pubmed: 21092934
Psychosom Med. 2001 Sep-Oct;63(5):697-710
pubmed: 11573016
Gastroenterology. 2018 Jul;155(1):47-57
pubmed: 29702118
J Psychosom Res. 2008 Feb;64(2):119-28
pubmed: 18222125
Biopsychosoc Med. 2014 Mar 21;8(1):10
pubmed: 24655428
Dig Dis Sci. 2003 Jul;48(7):1317-23
pubmed: 12870789
Biopsychosoc Med. 2007 Mar 03;1:6
pubmed: 17371576
Int J Psychiatry Med. 2018 May;53(3):159-170
pubmed: 29280689
Gastroenterology. 2006 Apr;130(5):1377-90
pubmed: 16678553
J Gastroenterol. 2021 Mar;56(3):193-217
pubmed: 33538894
Am J Physiol Gastrointest Liver Physiol. 2001 Apr;280(4):G519-24
pubmed: 11254476
Behav Res Ther. 2011 Jun;49(6-7):413-21
pubmed: 21565328